Frankfurt
31.03.26 | 08:01
0,017 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Acarix Q4 2025 presentation: Revenue up 26% as CADScor adoption accelerates | 13 | Investing.com | ||
| 12.02. | Acarix AB: Acarix Publishes Year-End Report 2025 | 135 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2025 year-end financial results. "Last year was a year of meaningful commercial and operational... ► Artikel lesen | |
| 11.02. | Acarix AB: Acarix Announces New Distribution Partner in Saudi Arabia for the CADScor System | 251 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix AB (Nasdaq Stockholm: ACARIX), a medical device company advancing noninvasive, AI enabled diagnostics for coronary artery disease, today announced that it has entered into a strategic... ► Artikel lesen | |
| 04.02. | Acarix AB: Acarix Receives EU MDR Certification for the CADScorSystem | 263 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announced that its CADScor System has successfully achieved certification under the European Union Medical... ► Artikel lesen | |
| 06.11.25 | Acarix AB Q3 Loss Drops | 9 | RTTNews | ||
| 06.11.25 | Acarix Q3 2025: Umsatzplus von 137 % beflügelt globalen Expansionskurs | 6 | Investing.com Deutsch | ||
| 06.11.25 | Acarix Q3 2025 presentation slides: 137% revenue growth amid global expansion | 5 | Investing.com | ||
| 06.11.25 | Acarix AB: Acarix Publishes Interim Report, Third quarter 2025 | 180 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the third quarter of 2025. The report highlights international... ► Artikel lesen | |
| ACARIX Aktie jetzt für 0€ handeln | |||||
| 27.10.25 | Acarix AB: Announcement from the general meeting in Acarix AB | 236 | GlobeNewswire (Europe) | The extraordinary general meeting 2025 (the "EGM") of Acarix AB ("Acarix" or the "Company") was held today on 27 October 2025 and the following resolutions were passed unanimously by the meeting.
Change... ► Artikel lesen | |
| 17.10.25 | Acarix AB: Acarix responds to G-BA decision on reimbursement in the German market | 250 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that G-BA reached a negative decision on the possibility for CADScor System to receive reimbursement... ► Artikel lesen | |
| 21.08.25 | Acarix AB: Acarix Reports Significant Progress Toward Fixed Reimbursement | 241 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that the company has achieved another milestone on its path toward fixed reimbursement... ► Artikel lesen | |
| 21.08.25 | Acarix AB: Acarix Publishes Interim Report, January - June 2025 | 240 | GlobeNewswire (Europe) | Malmö, Sweden (Aug. 21, 2025) - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the second quarter and first half of 2025. The... ► Artikel lesen | |
| 28.07.25 | Acarix AB: Acarix achieves new Fixed U.S. reimbursement milestone for CADScor at $300.00 USD | 346 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that a second payer has agreed to provide fixed reimbursement of $300 for the CADScor®... ► Artikel lesen | |
| 08.07.25 | Acarix AB: Acarix Enters MENA Region with First Major Order, Expanding Global Presence | 337 | GlobeNewswire (Europe) | Malmö, Sweden - July 8, 2025 - Acarix, a global pioneer in AI-driven and acoustics-based cardiac diagnostics, is proud to announce its first order in the Middle East and North Africa (MENA) region.... ► Artikel lesen | |
| 26.06.25 | Acarix AB: Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor System in U.S. Emergency Departments | 320 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®... ► Artikel lesen | |
| 16.06.25 | Acarix AB: Acarix Achieves First Fixed U.S. Reimbursement Milestone for CADScor at $300.00 USD | 313 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix a global leader in AI and acoustics-based cardiac diagnostics, is pleased to announce that the first payor has agreed to provide fixed reimbursement for the CADScor® System at... ► Artikel lesen | |
| 12.05.25 | Acarix AB: Acarix Publishes Interim Report, January - March 2025 | 419 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the first quarter of 2025. The report highlights continued growth in the U.S.... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 38,760 | -0,33 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 24,040 | 0,00 % | Dividendenbekanntmachungen (27.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1819 EUR BRT APARTMENTS CORP US0556453035 0,25 USD 0,2166 EUR CANADIAN IMPERIAL... ► Artikel lesen | |
| ECKERT & ZIEGLER | 14,690 | +0,69 % | Eckert & Ziegler: More to FY26 than meets the eye, chg.: Underlying momentum at EUZ remains strong, with supportive Lu-177/Ac-225 ... | The FY26 guidance points to stronger underlying momentum than the headline suggests. While the reported 2026 sales guidance of € 320m implies only 3% yoy growth, FX and lower licence revenues mask a... ► Artikel lesen | |
| UNITEDHEALTH | 230,00 | +0,68 % | UNITEDHEALTH GROUP INC im analytischen Fokus | ||
| HIMS & HERS HEALTH | 16,550 | +1,07 % | Canaccord reiterates Hims and Hers stock rating on Novo launch | ||
| BICO GROUP | 1,525 | +0,79 % | BICO Group AB: BICO Group AB has divested the Finnish property for a total of EUR 3.5m | BICO Group AB ("BICO") has completed the divestment of its property in Oulu, Finland, through the sale of BICO Real Estate Oy to Logistea AB ("Logistea"). The total sales price amounts to EUR 3.5m,... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,015 | -5,06 % | NuGen Medical Devices Inc.: NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology | Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering... ► Artikel lesen | |
| SPINEWAY | 0,149 | +0,13 % | Spineway: 2025 annual results | Ecully, February 17, 2026 - 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| UNIDOC HEALTH | 0,075 | +9,59 % | UniDoc stellt Installation des H3 Health Cube in Italien fertig | - Der KI-gestützte Health Cube steht
ab sofort den Patienten im Dorf Guardia Perticara in der italienischen Region Basilikata zur Verfügung.
VANCOUVER, British Columbia... ► Artikel lesen | |
| VERU | 2,130 | 0,00 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| CLARIANE | 3,516 | +0,40 % | Korian Stiftungsaward 2026 geht an "Rollstuhl-Erlebnisreisen GIAMBO gUG"- innovative Reisen für Menschen mit Assistenzbedarf | München (ots) - Der diesjährige Korian Stiftungsaward für Vielfalt und Respekt in der Pflege geht an die Rollstuhl-Erlebnisreisen GIAMBO gUG aus Hamburg. Die Korian Stiftung für Pflege und würdevolles... ► Artikel lesen | |
| SENSEONICS | 5,850 | +8,33 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| VIROMED MEDICAL | 5,150 | -0,96 % | VIROMED MEDICAL AG im Fokus ruhiger Neubewertung | ||
| BONESUPPORT | 17,510 | +3,61 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes year-end report 2025 | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the year-end report for the fourth quarter and full year 2025.
"Strong growth... ► Artikel lesen |
Das Unternehmen ACARIX AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,017 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACARIX AB finden Sie auf Wallstreet Online.